Synthetic RIG-I Agonist-Mediated Cancer Immunotherapy Synergizes with MAP-Kinase Inhibition against BRAF Mutated Melanoma

Investigators reported that the clinically relevant combination of MAP kinase pathway inhibitors Dabrafenib and Trametinib synergized with RIG-I agonist-induced immunotherapy to kill BRAF-mutated human and mouse melanoma cells.